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Expression of Phospholipase A2 Receptor in Pediatric 
Hepatitis B Virus-Related Membranous Nephropathy
Purpose: Hepatitis B virus (HBV) infection is among etiologies of secondary 
mem branous nephropathy (MN) in pediatric patients. We evaluated expression 
of phospholipase A2 receptor (PLA2R), a specific target antigen of primary MN, in 
pediatric HBV-related MN. 
Methods: We retrospectively reviewed patients with biopsy-proven HBV-related 
MN from the renal biopsy registry and electronic medical records of Severance 
Hospital, Seoul, Korea, from 1993 to 2004. Paraffin-embedded human kidney 
tissues were retrieved and immunohistochemically stained for PLA2R. 
Results: Ten pediatric patients with 13 biopsied specimens were reviewed. The 
predominant pathological stage was stage II–III, and second was stage II. The 
intensity of staining for IgG was greatest, with less intense staining for IgM, IgA, 
C3, C4, and C1q. All the patients had angiotensin-converting enzyme inhibitor 
combined with glucocorticoid, and four patients converted to cyclosporine treat-
ment from glucocorticoid monotherapy. Urinalysis of all the patients normalized 
after variable period. PLA2R staining was demonstrated in the outer glomerulus in 
3 out of 13 biopsies, 2 of which were obtained from the same patient over a 5-year 
interval.
Conclusions: PLA2R was expressed in a small number of cases diagnosed as 
pe diatric HBV-related MN, indicating that some HBV-related MN cases may be 
primary MN concurrent with HBV infection.
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Introduction
Membranous nephropathy (MN) is a pathological entity defined by the 
presence of subepithelial immune deposits that induce a spectrum of changes 
in the glomerular basement membrane. MN can be divided into primary and 
secondary forms. The majority of primary MN cases are understood to be 
mediated by an autoantibody to phospholipase A2 receptor (PLA2R) expressed 
on podocytes1). MN may also occur secondary to other conditions, with in­
fection as one etiology. In contrast to primary MN, the immune complex of 
secondary MN is likely to derive from non­glomerular antigen from the spe­
cific etiologic agent. MN arising in the background of hepatitis B virus (HBV) 
infection has been understood as secondary MN. In children, primary MN is 
a much less common etiology of nephrotic syndrome2), and secondary forms 
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of MN are more common3). Although the pathogenesis is 
shared in primary MN and secondary MN associated with 
HBV, the clinical course and treatment is quite different. As 
approximately one third of primary MN spontaneously 
resolve at 10 years follow up4), HBV­MN in children resolves 
spontaneously in many cases, in association with serocon­
version of hepatitis B e­antigen (HBeAg)5). The treatment 
of primary MN is either conservative therapy, or immuno­
suppressive treatment, which is considered for those in risk 
of progression, after assessment of several pathologic and 
clinical prognostic factors6). Antiviral therapy is usually 
sufficient for most of the HBV­MN cases7). However, the 
association between primary MN and HBV­MN has not 
been well­investigated. Because data on PLA2R expression 
in HBV­related MN have been lacking, the true incidences 
of primary and secondary MN in HBV infection are not 
yet known, as well. Therefore, we evaluated PLA2R expres­
sion in biopsy­proven MN cases associated with HBV. 
Materials and methods
1. Case retrieval and clinicopathological review
We retrieved 10 childhood patients with biopsy­proven 
HBV­related MN from the renal biopsy registry and elec­
tronic medical records of Severance Hospital, Seoul, Korea, 
from the years 1993 to 2004. Clinical history and histolo­
gical data were collected by reviewing electronic medical 
records. 
2. Immunohistochemical staining of PLA2R
Paraffin­embedded human kidney tissues from 10 pati­
ents were obtained from the surgical pathology archive of 
the Department of Pathology, Yonsei University, Severance 
Hospital (Seoul, South Korea). Paraffin­embedded samples 
were cut into 4­μm sections, deparaffinized, and rehydrated 
with a graded series of alcohol and water. Heat­induced 
antigen retrieval was performed in Bond Epitope Retrieval 
Solution 2 (Leica Microsystems, Ltd., Wetzlar, Germany) 
at 98℃ for 20 minutes. Kidney tissues were stained using 
the Bond­III automated staining platform (Leica Micro­
systems, Ltd.). Endogenous peroxidase activity was blocked 
by incubation with 0.3% hydrogen peroxide for 10 minutes. 
The tissue sections were then incubated overnight with a 
primary antibody against PLA2R (dilution 1:2,000; Sigma­ 
Aldrich, St. Louis, MO, USA) at 4℃, followed by incubation 
with Bond Polymer Refine Detection reagent (Leica). This 
study was approved by the Institutional Review Board of 
Severance Hospital (4­2014­0828).
Results
The retrieved cases included 13 biopsies from 10 patients. 
Baseline patient demography is shown in Table 1. The me­
dian age was 9.54 years (range 3–15). A total of 10 biopsies 
(76.9%) were from males and 3 biopsies were from females 
(23.1%). Stage II–III was the predominant pathological stage, 
representing 46.2% of cases, with stage II as the second most 
predomi nant (38.5%). The median number of glomeruli 
per biopsied tissue was 41.6 (range 14–139). The intensity 
of immuno fluorescent staining for IgG was 2+ or 3+ in 11 
cases (84.6 %), whereas staining intensities for IgA, C4, and 
C1q were no more than 1+. Pathologic findings in favor of 
secondary HBV­related MN such as mesangial hypercel­
lularity, me sangial widening, and electron­dense deposits 
in mesangium were noted in four patients, and all of them 
were PLA2R­negative. All the patients started treatment at 
a similar point when they were pathologically diagnosed as 
mem branous nephropathy. The treatment was conserva­
tive agent such as angiotensin­converting enzyme inhibitor 
and glucocorticoid. Four patients who did not respond well 
to glucocorticoid or had much severe symptoms such as 
nephrotic syndrome, received more aggressive immuno­
suppressive agents like cyclosporine A. Two out of the 4 
patients had interferon­alpha following cyclosporine A, 
which was used for a treatment of active B­viral hepatitis. 
After a period ranging from 3 months to 22 months, all 
the patients were free of proteinuria and hematuria with 
seroconversion of HBeAg to anti­hepatitis B e­antibody 
(anti­HBe­Ab). Three cases stained positive for PLA2R 
along the outer surface glomerular capillary walls (Fig. 1); 
two of these cases were biopsied from the same patient over 
a 5­year interval. Patient demographics, pathological fin­
dings, immunofluorescence findings, electron microscopy 
findings, and treatment were comparatively analyzed in 
between PLA2R negative and positive groups, but no stati­
stically significant results were obtained. Immunohisto­
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chemistry for hepatitis B core antigen (HBcAg) had been 
performed at the time of biopsy in some cases, with nega­
tive results. 
Discussion 
After the development of the Heymann nephritis model, 
MN has been understood to be caused by autosensitization 
8). Although megalin was soon identified as a target antigen 
in rat9), PLA2R was only recently identified as a target anti­
gen in humans1). During the decade since that discovery, 
much has been learned about the biological nature and 
clinical significance of PLA2R in the diagnosis and treat­
ment of MN10). PLA2R is a transmembrane receptor of 
mannose receptor family that constitutively undergo en­
docytosis. Thus, on PLA2R immunohistochemical stain, 
it appears as weak background staining on the cytoplasm 





























UA normal (3) After 4 years 
2 11 M II–III 21 - ++ + + - - - FSGS in 1 
glomerulus
Subepithelial and
no mesangial EDD 
Cyclosporine A (3) UA normal (22) After 5 years
2 13 M II–III 14 - + + + - - - - ACE inhibitor and 
glucocorticoid
3 9 F III 28 - ++ ++ ++ - + - - Cyclosporine A
(13)
3 10 F II 36 - ++ + + - - - - UA normal (4)
4 13 M II 15 - ++ - - - + + - ACE inhibitor and 
glucocorticoid
UA normal (29)
5 7 M II–III 62 - ++ - + - + - Subepithelial EDD 
and mesangial slight 
widening with some 
EDD
ACE inhibitor and 
glucocorticoid
UA normal (1)
6 5 M II–III 139 - ++ - - + - - - Cyclosporine A 
(23) and alpha-
interferon (4–6)
UA protein free 
(13)
After 3 years









UA protein free 
(6), relapse (13) 
and UA normal 
(24)
After 3 years 





cellularity in 3 
glomeruli
- ACE inhibitor and 
glucocorticoid
UA normal (6) After 2 months 
10 3 M II 39 - +++ - ++ - - + - ACE inhibitor and 
glucocorticoid




After 3 years 
10 8 M II–III 17-19 - + - - - - + - ACE inhibitor and 
glucocorticoid
Abbreviations: ACE, angiotensin-converting enzyme; EDD, electron-dense deposits; FSGS, focal segmental glomerulosclerosis; UA, urinalysis. 
* and **. Histopathological findings in favor of secondary HBV-MN such as EDD are noted.
†UA normal is defined as urine free of hemoglobin and protein. Number in parentheses is the period from first renal biopsy date to achieve normal UA. 
‡Period from first renal biopsy date to achieve seroconversion of anti-HBe-Ab is noted. IgA, IgG, IgM, C3, C4, and C1q as immunofluorescence results, and 
PLA2R as immunohistochemical stain results.
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of podocytes. In contrast, PLA2R­positive MN shows strong 
PLA2R immunohistochemical positivity in subepithelial 
space, indicating the subepithelial presence of immune­
complex deposits including PLA2R11). Glomerular subepi­
thelial PLA2R expression has even become one of the es­
sential diagnostic features of primary MN12). Secondary 
forms of MN are likely to involve immune responses to 
non­glomerular antigens, either those planted on the glo­
merular basement membrane and bound in situ by circula­
ting antibodies or circulating antigens in the form of anti­
gen­antibody complexes deposited in the subepithelial area. 
Etiologies for secondary MN include autoimmune rheu­
matologic disease, therapeutic agents such as gold or peni­
cillamine, malignancy, and infection3). In children, infec­
tion and autoimmune disease are the most common causes 
of secondary MN13).
HBV­related MN is a well­known example of secondary 
MN. Its incidence is thought to be higher among pediatric 
patients than in adult HBV­infected patients14­16). Most child­
ren infected with HBV will become chronic carriers14), while 
the majority of adults seroconvert, with disappearance of 
hepatitis B surface antigen (HBsAg), HBeAg, and HBV 
DNA15). HBeAg has been demonstrated within glomerular 
immune deposits of HBV­related MN5,17) and HBcAg has 
also demonstrated in glomerular deposits of two­thirds of 
the children infected with HBV18). Unfortunately, our data 
regarding HBcAg expression did not aid in distinguishing 
between primary and secondary MN. 
Histologic features, such as mesangial/endocapillary 
hypercellularity or immune deposits in locations other than 
the subepithelial space, are more frequently observed in 
secondary MN19), and some of our cases showed such fin­
dings. However, no single morphology is pathognomonic 
for distinguishing between primary and secondary MN. 
Although PLA2R is a reliable marker of primary MN, not 
every primary MN is associated with PLA2R. PLA2R is 
identified in about 80% of primary MN20), whereas throm­
bospondin type­1 domain­containing 7A (THSD7A) is 
detected in 10% of PLA2R­negative patients21). In addition, 
it has been demonstrated that childhood primary MN 
showed weaker PLA2R staining than that observed in 
adult patients22). In our study, PLA2R was present in a small 
A B 
C 
Fig. 1. Representative photos of positive (A) and negative (B) immunohistochemical staining for 
PLA2R, and granular immune deposits of IgG on immunofluorescent stain (C). As PLA2R stains 
strongly in subepithelial space (A), it stains weakly in cytoplasm of podocytes (B) which physio-
logically recycles from the plasma membrane and cytoplasm via endocytosis, which is a normal 
background finding. Both the PLA2R and IgG are stained granular along capillary loops, indica-
ting the subepithelial presence of immune deposits containing PLA2R and IgG, respectively.
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number of cases (2 out of 10 patients, and 3 out of 13 biop­
sies), meaning that some cases of MN in the background 
of HBV may not represent true secondary MN. Svobodova 
et al. also reported that two cases of HBV­related MN 
showed PLA2R positivity; however, they did not include 
PLA2R­negative cases among their study subjects23). Cases 
of hepatitis C virus­related MN showing PLA2R­positivity 
have been also reported24). The prevalence of PLA2R­posi­
tivity in “secondary” forms of MN varies; several studies 
have shown low prevalence while one retrospective study 
has shown 64 percent of PLA2R­positivity in 39 cases of 
HBV­MN25). THSD7A has been demonstrated to provide 
causal relationship between gallbladder carcinoma and 
the development of MN26). However, few studies have inve­
stigated the mechanism of PLA2R positivity in secondary 
MN. Some suggest coincidence of PLA2R­positive primary 
MN with secondary MN27), and others suggest the immu­
nologic background of secondary disease such as sarcoi­
dosis or hepatitis B might trigger immunization against 
PLA2R28). Therefore, it seems that discriminating primary 
and secondary MN based solely on PLA2R is inappropriate, 
and more study is needed to validate the association bet­
ween PLA2R­positive MN and HBV­MN. As all the patients 
in our study achieved remission on urinalysis with sero­
conversion, HBV­related MN seems to be more likely on 
clinical context in spite of the PLA2R positivity.
Distinguishing primary from secondary MN in the 
background of HBV infection has clinical significance 
because anti­viral therapy may be effective in controlling 
secondary MN29). The limitation of our study is that it is 
retrospective, which made use of archival paraffin­em­
bedded tissues. Because the incidence of childhood HBV­
related MN has decreased markedly in recent years, all the 
cases included were collected during the 1990s and early 
2000s. Lack of clinical data limited multifactorial analysis. 
Tests for THSD7A or IgG subtype analyses (to verify IgG4 
dominancy in primary MN) were not performed because 
the amount of tissue was insufficient. 
Conclusion: Some HBV­related MN in children showed 
glomerular PLA2R expression. In these cases the possibility 
of primary MN superimposed on HBV infection cannot 
be ruled out.
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